These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14581891)

  • 1. Trials of arsenic trioxide in multiple myeloma.
    Hussein MA
    Cancer Control; 2003; 10(5):370-4. PubMed ID: 14581891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
    Hussein MA
    Med Oncol; 2001; 18(4):239-42. PubMed ID: 11918450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the use of arsenic trioxide: leukemias and beyond.
    Chen Z; Chen GQ; Shen ZX; Sun GL; Tong JH; Wang ZY; Chen SJ
    Semin Hematol; 2002 Apr; 39(2 Suppl 1):22-6. PubMed ID: 12012319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-biomodulation with arsenic trioxide in multiple myeloma.
    Gallagher RE
    Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
    [No Abstract]   [Full Text] [Related]  

  • 5. Arsenic trioxide in multiple myeloma: rationale and future directions.
    Anderson KC; Boise LH; Louie R; Waxman S
    Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
    Bonati A; Rizzoli V; Lunghi P
    Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide: an ancient drug revived.
    Zhou J
    Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
    Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
    Deaglio S; Canella D; Baj G; Arnulfo A; Waxman S; Malavasi F
    Leuk Res; 2001 Mar; 25(3):227-35. PubMed ID: 11226519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
    Berenson JR; Yeh HS
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):192-8. PubMed ID: 17229334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
    Röllig C; Illmer T
    Cancer Treat Rev; 2009 Aug; 35(5):425-30. PubMed ID: 19464807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
    Lengfelder E; Hofmann WK; Nowak D
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide: an anti cancer missile with multiple warheads.
    Gazitt Y; Akay C
    Hematology; 2005 Jun; 10(3):205-13. PubMed ID: 16019469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L; Wang J; Hu X; Xu X
    Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
    Tallman MS
    Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
    Sui M; Zhang Z; Zhou J
    Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nursing considerations for nontraditional treatment approaches to hematologic malignancies.
    ONS News; 2004; 19(9 Suppl):67-8. PubMed ID: 15478594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.